𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Quality of life rapidly improves with budesonide therapy for active Crohn's disease

✍ Scribed by Dr. E. Jan Irvine; Gordon R. Greenberg; Brian G. Feagan; Francois Martin; Lloyd R. Sutherland; Alan B. R. Thomson; Lars-Goran Nilsson; Tore Persson

Publisher
John Wiley and Sons
Year
2000
Tongue
English
Weight
680 KB
Volume
6
Category
Article
ISSN
1078-0998

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Linear growth improves during infliximab
Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease
✍ Thomas D. Walters; Ashley R. Gilman; Anne M. Griffiths πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 106 KB πŸ‘ 2 views

## Background: The efficacy of infliximab as maintenance therapy in patients with otherwise chronically active crohn's disease (cd) is well established. data concerning the linear growth response are sparse and can only be accrued in children. ## Methods: From september 2000 to february 2004, 32

Short pediatric Crohn's disease activity
Short pediatric Crohn's disease activity index for quality improvement and observational research
✍ Michael D. Kappelman; Wallace V. Crandall; Richard B. Colletti; Anthony Goudie; πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 127 KB

Background: Practical and objective instruments to assess pediatric Crohn's disease (CD) activity are required for observational research and quality improvement. The objectives were: 1) to determine the feasibility of completing the Pediatric Crohn's Disease Activity Index (PCDAI) and the Abbreviat

Rasagiline improves quality of life in p
Rasagiline improves quality of life in patients with early Parkinson's disease
✍ Kevin M. Biglan; Steven Schwid; Shirley Eberly; Karen Blindauer; Stanley Fahn; T πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 164 KB πŸ‘ 1 views

The objective of this study was to determine the effects of rasagiline as monotherapy on quality of life (QOL) in patients with early Parkinson's disease (PD). Rasagiline, a potent, second-generation, irreversible, selective monoamine oxidase B inhibitor improves PD symptoms in patients with early P